Antibody-Drug Conjugates: Cancer Therapies to Watch
There are up to 80 ADCs in clinical development with close to 600 ongoing trials.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
Can Advocacy Groups Provide Useful Patient-Centered Data?
A survey presented during ASCO20 found that patients who considered themselves adequately informed felt “in control” most days.
Positive vs Negative Lymph Nodes Portend Worse Prognosis in Stage 3 RCC
In a study involving stage 3 RCC patients, those with positive lymph nodes had markedly inferior 5-year survival compared with those with lymph-node negative disease and 5-year survival similar to those with stage 4 RCC.
Antitumor Activity Reported With Lenvatinib/Pembrolizumab in Metastatic RCC After Disease Progression on ICI Therapy
Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.
Phase 3 PROSPER RCC Trial to Evaluate Neoadjuvant/Adjuvant Immunotherapy in Nonmetastatic RCC
The phase 3 PROSPER RCC trial will evaluate neoadjuvant with adjuvant nivolumab among patients with nonmetastatic RCC compared with surgery and standard-of-care surveillance.
Tivozanib Superior to Sorafenib in Heavily Pretreated Renal Cell Carcinoma
Tivozanib resulted in superior PFS compared with sorafenib among patients with RCC that progressed on 2 or 3 prior systemic regimens, including another VEGF inhibitor, according to the final analysis of the TIVO-3 trial.
Response-Based Addition of Ipilimumab to Nivolumab Not Effective in RCC
The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to results of a phase 2 trial.
HIF-2α Inhibitor Demonstrates Promising Activity Against VHL-Associated RCC
A HIF-2α inhibitor demonstrated antitumor activity against VHL-associated clear cell RCC and other associated tumors, according to interim results of a phase 2 study.
Nivolumab Plus Ipilimumab Demonstrated Promising Activity in Previously ICI-Treated RCC
Preliminary phase 2 data suggest that nivolumab plus ipilimumab was efficacious in advanced RCC that previously progressed with immune checkpoint inhibitor therapy.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Pembrolizumab-Axitinib Continued to Offer Durable Benefits in Advanced RCC
Updated findings from KEYNOTE-426 showed that frontline pembrolizumab-axitinib continued to be associated with improved PFS and OS compared with sunitinib in advanced RCC.
Savolitinib Shows “Encouraging Efficacy” in MET-Driven Papillary RCC
Savolitinib vs sunitinib demonstrated numerically better PFS, OS, and safety among patients with MET-driven papillary renal cell carcinoma.
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Lymph Node Dissection Offers No Survival Advantage in T2-T3 RCC
In a study of T2 to T3 RCC patients, lymph node dissection did not significantly improve overall survival.
Expanded Use of Partial Nephrectomy Shows Promise
Separate studies demonstrated that partial nephrectomy could be an acceptable alternative to radical nephrectomy in selected cases of high-risk kidney cancer and large renal masses.
Death Rate From Low-Risk RCC Rises With Age Regardless of Treatment Modality
Among patients who undergo treatment for T1a renal cell carcinoma, 5- and 10-year cancer-specific mortality rates rise with age across treatment modalities, a study found.
Studies Back Active Surveillance for Small Renal Masses
Active surveillance for small renal masses in older patients offers long-term oncologic efficacy similar to that of partial or radical nephrectomy.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
